Research programme: pain therapeutic - Taisho

Drug Profile

Research programme: pain therapeutic - Taisho

Alternative Names: NMDA receptor antagonists - Taisho; NR2B receptor antagonist - Taisho; Pain therapeutic research programme - Taisho

Latest Information Update: 17 Apr 2012

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class
  • Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 31 Dec 2010 Discontinued - Preclinical for Pain in Japan (PO)
  • 06 Sep 2004 Preclinical trials in Pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top